Ocumetics has positive intraocular lens results

Executive Summary

• Ocumetics Technology Corp. reported positive three-month postoperative results from Group 1 patients in its first-in-human clinical study of its accommodating intraocular lens.
• The results validated the company's core technology, meeting or exceeding all predefined internal benchmarks for safety, lens delivery, and foundational distance visual performance.
• The success of Group 1 has de-risked the technology and allowed Ocumetics to initiate planning for Group 2 surgeries, with refinements to the lens delivery mechanism already implemented based on surgeon feedback.

Key Details

• Study Phase: First-in-human early feasibility study.
• Patient Profile: Group 1 patients entered with severe visual impairment, with some having uncorrected preoperative acuities as poor as 20/250 (consistent with legal blindness).
• Safety Outcomes: All patient outcomes met safety expectations; no adverse safety events reported that would halt progress.
• Visual Acuity: Visual acuity outcomes met and exceeded expectations. Patients reported life-changing improvements, including the ability to read, drive, and perform everyday activities.
• Lens Delivery: The lens delivery system met expectations.
• Operational Updates:
  • Refinements to the lens delivery mechanism have been implemented based on Group 1 insights.
  • Manufacturing and testing of optimized lens designs are currently underway.
  • Group 2 surgeries are expected to be scheduled following the completion of final lens testing and validation.
• Upcoming Event: A webinar featuring CEO Dean Burns to discuss the three-month study results is scheduled for Wednesday, Feb. 4, 2026, at 4 p.m. ET.

Notable Quotes

• Dean Burns, President and CEO: "These first-in-human results are exactly what we were aiming to demonstrate at this stage: safe implantation, reliable delivery and strong visual outcomes... I remain 100 per cent confident in our accommodating intraocular lens technology. Based on this success, we have initiated planning for group 2 surgeries."
• Dr. Rafael Vazquez, MD, Principal Investigator: "All patient outcomes have met safety expectations... From being classified legally blind, my patients can now read, enjoy everyday life activities and drive. The impact on their independence and sense of freedom has been remarkable."